Lifeward (LFWD) Stock Price

Lifeward Price

NASDAQ·CLOSED
6.99
+0.00 (+0.00 %)
Market closed

Over the last 12 years Lifeward grew revenue by 31.4% annually, reaching 25.66 M USD. For Lifeward, the net margin of -112.8% is up versus -295.4% a few years ago. The consensus 12-month price target for Lifeward is 7.40 USD, about 5.8% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 52% above its 52-week low.

Lifeward stock price

Access this data via the Eulerpool API

Lifeward business model & stock analysis

Rewalk Robotics Ltd is a publicly traded company specializing in the development and manufacture of exoskeletons that enable individuals with spinal injuries or paralysis to regain mobility. It was founded in 2001 and is based in Marlborough, Massachusetts. The company's goal is to provide individuals with mobility impairments the opportunity for greater freedom of movement and improved quality of life. Rewalk Robotics has launched various products in the field of rehabilitation and industrial applications, and it continues to research and develop new applications for its technology. The exoskeletons use a combination of motors, sensors, and control systems to allow users to stand, walk, and even climb stairs. In addition to medical applications, Rewalk Robotics also provides exoskeletons for industrial use, enhancing worker safety and productivity. The company is actively involved in research and development to expand the therapeutic possibilities of exoskeletons for neurologic conditions such as stroke and Parkinson's disease. Rewalk Robotics is dedicated to innovation and technology, aiming to improve the lives of millions worldwide by providing greater mobility and autonomy.

Frequently asked questions about Lifeward

Rewalk Robotics Ltd is a company specializing in the development and commercialization of exoskeleton systems that assist individuals with mobility impairments. Their business model revolves around offering innovative solutions to enhance the quality of life for people with spinal cord injuries, stroke survivors, and other neurological conditions. With a focus on research, development, and production of their robotic exoskeletons, Rewalk Robotics aims to improve mobility, independence, and overall well-being for individuals facing mobility challenges. By combining advanced technology and extensive medical expertise, Rewalk Robotics Ltd strives to be at the forefront of the assistive device industry, providing life-changing solutions for those in need.

Rewalk Robotics Ltd is primarily active in the healthcare and medical device industry.

Rewalk Robotics Ltd faces competition from various companies in the market. Some of its main competitors include Ekso Bionics Holdings, Inc., Parker Hannifin Corporation, and Rex Bionics PLC. These competitors also focus on developing and providing innovative robotic exoskeleton solutions and rehabilitation technologies. However, Rewalk Robotics Ltd continues to stand out by leveraging its unique patented designs and advanced functionalities, catering to the specific needs of individuals with mobility impairments.

Rewalk Robotics Ltd is a leading innovative medical device company that designs and develops wearable robotic exoskeletons to help individuals with lower limb disabilities regain their mobility. Founded in 2001, Rewalk Robotics has been dedicated to transforming the lives of people with spinal cord injuries, allowing them to walk again with greater independence. The company's advanced technology combines artificial intelligence, motion sensors, and motorized systems to provide users with enhanced mobility and improved quality of life. Rewalk Robotics has gained global recognition for its groundbreaking solutions and continues to strive for advancements in the field of robotic rehabilitation.

Rewalk Robotics Ltd has achieved several significant milestones since its inception. One of the notable accomplishments is the development and commercialization of their exoskeleton technology, revolutionizing the lives of individuals with lower limb disabilities. The company has successfully obtained regulatory approvals for their innovative designs in various regions, enabling broader market access. Additionally, Rewalk Robotics Ltd has formed strategic partnerships with leading healthcare providers and institutions, fostering collaborations to improve patient outcomes. These milestones highlight the company's commitment to advancing the field of robotics for functional mobility and improving the quality of life for individuals with mobility impairments.

Rewalk Robotics Ltd is primarily present in several countries and regions across the world. The company has a global presence and operates in various key markets, including the United States, Europe, Asia, and beyond. With its cutting-edge assistive technologies for individuals with mobility impairments, Rewalk Robotics Ltd has made significant strides in expanding its reach internationally. The company's commitment to improving the lives of individuals with spinal cord injuries and other mobility challenges has garnered recognition and adoption across different parts of the globe.

Rewalk Robotics Ltd represents values of innovation, determination, and commitment to improving the lives of individuals with lower limb disabilities. The company's corporate philosophy revolves around creating advanced robotic exoskeletons that enable individuals to walk again. By incorporating cutting-edge technology and continuous research and development, Rewalk Robotics strives to enhance mobility, increase independence, and improve overall quality of life for its users. Through a strong focus on user-centric design and collaboration with medical professionals, Rewalk Robotics Ltd aims to provide effective and personalized solutions to help individuals regain their independence and reintegrate into society.

Analysts currently set an average price target of 7.40 USD for the Lifeward stock (median: 7.40 USD), implying +5.8 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the Lifeward stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Lifeward to generate revenue of 25.24 M USD and earnings per share of -12.00 USD.

Converted at the current exchange rate, the Lifeward share trades at 6.13 EUR (6.99 USD).

The Lifeward share (LFWD) is listed on 3 stock exchanges, including: NASDAQ (RWLK), Frankfurt (2RW.F), München (2RW.MU).

Rewalk Robotics Ltd is a leading company in the development of robotics technologies that assist people with reduced mobility capabilities. The company is based in Yokneam, Israel, and was founded in 2001. The company operates in several sectors, including the medical and rehabilitation industry, the military and security industry, and the leisure and entertainment industry. The main product of Rewalk Robotics is the ReWalk Rehabilitation Exoskeleton suit. This state-of-the-art suit allows people with spinal cord injuries to stand and walk again. The suit supports the user's limbs and improves their posture and mobility. The product has been very successful in the medical and rehabilitation industry, as it provides people with greater independence and improved self-confidence. Rewalk Robotics also has a military and security-oriented division. The company is currently developing a range of robots that can be used in emergency situations, disaster relief, or combat zones. The robots can perform tasks such as intercom systems, weapon transport, remote control of vehicles, and much more. This division of the company is rapidly growing and has a lot of potential. Another important area of Rewalk Robotics is the leisure and entertainment industry. The company offers a variety of products that help people with mobility issues to participate in sports and other physical activities. These include racing wheelchairs, adaptive sports clothing, and much more. Rewalk Robotics is known for its innovation and has received a number of awards in recent years. The company is constantly striving to improve its products and has been successful in doing so. It has a broad customer base and works closely with governments, healthcare institutions, and other companies to bring its products to market. Overall, Rewalk Robotics has a successful business model that targets the needs of people with mobility issues. The company has a clear vision and is constantly working to improve its products to achieve the best results. With advancing technology and an increasing demand for mobility solutions, the company has enormous growth opportunities and will play an important role in the future.

The expected revenue of Lifeward is 25.24 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Lifeward is -104.25 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Lifeward is currently -0.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lifeward stock.

The price-to-sales ratio (P/S) of Lifeward is currently 2.41. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lifeward stock.

The Eulerpool Quality Score for Lifeward is 4/10.

The ISIN of Lifeward is IL0011331076. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Lifeward is A12BMB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Lifeward is LFWD. The ticker symbol is used to trade Lifeward shares on the stock exchange.

Lifeward paid dividends every year for the past 0 years.

Lifeward is assigned to the 'Health' sector.

The dividends of Lifeward are distributed in USD.

Fair ValueTerminal
5.73 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
523,734.69 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website rewalk.com
Country
Israel
Currency
USD
Initial public offering
Sep 12, 2014
ISIN
IL0011331076
Cusip
M8216Q200
Sedol
BQKHN58
Market capitalization
127.85 M USDMicro Cap
52-Week Range
4.59–9.94USD
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2025
-0.31
P/Ee 2026
-0.58
P/Ee 2027
-2.46
P/Ee 2028
-6.15
P/Ee 2029
26.88
P/S
P/Se
2.43
EV/EBIT
—
P/B Ratio
6.78
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-153.55 %
Gross Margin
32.01 %
EBIT Margin
-75.94 %
Net Margin
-112.78 %
EPS (Earnings Per Share)
-3.33 USD
Net Debt / EBIT
0.35
Debt/Equity
0.00
Last updated Sep 27, 2026, 12:17 PM

Lifeward Peer Group

Lifeward Ticker

FRANKFURT · 2RW.FMUNICH · 2RW.MUNASDAQ · RWLK

Lifeward FIGI

RWLK:US · BBG006SYKFN0RWLK:UA · BBG006SYQG98RWLK:UC · BBG006SYQGB5RWLK:UN · BBG006SYQGD3RWLK:UP · BBG006SYQGF1RWLK:UB · BBG006SYQGH9RWLK:UM · BBG006SYQGK5RWLK:UX · BBG006SYQGL4RWLK:UR · BBG006SYQGM3RWLK:UD · BBG006SYQGS7RWLK:UF · BBG006SYQGW2RWLK:VY · BBG006SYQGX1

All fundamentals and in-depth analysis of Lifeward

Our stock analysis for Lifeward stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lifeward. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.